Paclinab

Paclinab is a microtubule inhibitor indicated for the treatment of patients with Metastatic breast cancer, locally advanced or metastatic non - small cell lung cancer, Metastatic adenocarcinoma of pancreas.

It is recommended by guidelines such as NCCN and ESMO as first - line regimens in metastatic pancreatic cancer in combination with gemcitabine and in non - small cell lung cancer in combination with carboplatin.

INDICATION

• Metastatic Breast Cancer: Paclinab is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.
• Non - Small Cell Lung Cancer: Paclinab is indicated for the first - line treatment of locally advanced or metastatic non - small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.
• Adenocarcinoma of the Pancreas: Paclinab is indicated for the first - line treatment of patients with metastatic adenocarcinoma of the pancreas, in combination with gemcitabine.